20362
ORBO™ 92 Carboxen® 564 (20/45), 160/80 mg
W,F,F separators, O.D. × L 6 mm × 75 mm, pkg of 25 ea, for analyte group Vinyl acetate
Sign Into View Organizational & Contract Pricing
All Photos(1)
Synonym(s):
ORBO™ Carboxen-564 Tube
EC Number:
UNSPSC Code:
47131900
Recommended Products
material
W,F,F separators
Quality Level
Agency
NIOSH 1453
OSHA 51
product line
ORBO™
composition
Bed A, 160 mg
Bed B, 80 mg
packaging
pkg of 25 ea
manufacturer/tradename
ORBO™ 92
technique(s)
active air sampling: suitable
O.D. × L
6 mm × 75 mm
matrix
Carboxen® 564 Carbon Molecular Sieve (CMS)
application(s)
air monitoring
environmental
industrial hygiene
compatibility
for analyte group Vinyl acetate
Related Categories
General description
- ORBO™ 92 Carboxen® 564 (20/45), 160/80 mg solvent desorption tube is designed for gas and vapor sampling.
- It contains two beds of the same selective adsorbent separated by glass wool or foam.
- Dual-layer or two-bed construction of the tube allows for any sample breakthrough to be captured in the smaller back-up bed.
Legal Information
Carboxen is a registered trademark of Merck KGaA, Darmstadt, Germany
ORBO is a trademark of Sigma-Aldrich Co. LLC
WGK
nwg
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Personal Protective Equipment
dust mask type N95 (US), Eyeshields, Gloves
Regulatory Information
新产品
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Anne Ørbo et al.
The Journal of steroid biochemistry and molecular biology, 113(1-2), 139-149 (2009-01-14)
Patients with endometrial hyperplasia representing preliminary stages of endometrial cancer have shown to respond to therapy in 100% of the cases when treated with levonorgestrel-impregnated intrauterine device. Anti-proliferative effect has also been reported after application of an anti-progestin impregnated intrauterine
A Orbo et al.
International journal of oncology, 5(3), 619-625 (1994-09-01)
About 50% of the cases with invasive carcinoma of the uterine cervix occurs before menopause. Cyclic changes of sex steroids may therefore interfere with the ratio between extracellular levels of cGMP and cAMP (cGMP(ex)/cAMP(ex)). This ratio has been proposed as
Anne Beate Vereide et al.
Gynecologic oncology, 97(3), 740-750 (2005-05-12)
The aim of the study was to investigate apoptosis as a growth regulatory mechanism of gestagen in endometrial precancers and to compare differences in the apoptotic cascade after high and low dose gestagen regimens. Pre- and post-treatment paraffin-embedded endometrial hyperplasia
H Stalsberg et al.
Virchows Archiv. A, Pathological anatomy and histopathology, 414(5), 415-422 (1989-01-01)
The autopsies of 12 victims from two snow avalanches in North-Norway are reported. Supportive evidence from non-autopsied and surviving victims is included. Consistent autopsy findings were prominent lung oedema, moderate cerebral oedema, extreme contraction of the left ventricle, petechiae in
Anne Ørbo et al.
Anticancer research, 35(12), 6401-6409 (2015-12-08)
To investigate if a levonorgestrel-impregnated intrauterine system (LNG-IUS) was more efficient compared to oral progestin in the clearance of the paired box 2 gene (PAX2) - and phosphatase and tensin homolog (PTEN)-null endometrial glands and assess the significance of PAX2-
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service